甲地孕酮提高肿瘤病人化疗期间耐受性的临床观察  

Clinical study of Megestrol Acetate for Improving Endurance of Cancer Patients in Chemotherapy

作　　者：郭绍兰[1] 王若雨[1] 冀学宁[1] 葛日光[1] 全秀莲[1] 吴忠[1] 

机构地区：[1]大连大学附属中山医院肿瘤科,辽宁大连116001

出　　处：《大连大学学报》2008年第6期100-101,共2页Journal of Dalian University

摘　　要：从2003年–2007年,将同期入院的69例晚期癌症患者随机分为联合宜利治组及化疗组,观察食欲改善情况、恶心呕吐反应及KPS评分指标。联合组食欲有反应84.3%(27/32),而对照组59.5%(22/37),组间比较差异有显著性(P<0.01)。联合组恶心呕吐无反应68.7%(22/32),对照组47.5%(17/37),组间比较差异有显著性(P<0.01);KPS评分增加10分56.2%(18/32),对照组18.9%(7/37),组间比较差异有显著性(P<0.01)。甲地孕酮提高恶性肿瘤患者化疗期的耐受性有较好疗效。From 2003 to 2007, the hospitalized cancer patients with later stage, 69 cases were divided into two group, chemotherapy and chemotherapy plus megestrol acetate. The situation of improved appetite, reaction of nausea and vomiting and KPS score were studied. Reaction rate of good appetite in combining group and control group was 84.3% （27/32） and 59.5%（22/37）, respectively. There was significant difference, （P 〈0.01）. No reaction rate of nausea and vomiting in combining group and control group was 68.7% （22/32） and 47.5% （17/37）, respectively. There was significant difference, （P 〈0.01）. The rate of increasing 10 KPS score in combining group and control group was 56.2% （18/32） and 18.9%（7/37）, respectively. There was significant difference, （P 〈0.01）. Megestrol acetate contributed to improve the endurance of cancer patients in chemotherapy.

关 键 词：甲地孕酮 肿瘤 化疗 

分 类 号：R730[医药卫生—肿瘤]